The manufacturer of Solaraze gel
Today, we live in an environment where mega thermal climate, fueled by the El Nino phenomenon, is prevalent. The temperature in our daily lives is generally rising, especially in densely-populated areas. Due to long exposure to sunlight over a long period of time, some people suffer from sun damage, a condition known as solar keratosis.
There is a non-steroidal anti-inflammatory dermatological gel that is FDA approved called Solaraze (Diclofenac Sodium Gel) that can be used to treat solar keratosis. Its main ingredient is Diclofenac and hyaluronic acid, whose supplier is Stanford Chemicals, a major hyaluronic acid supplier in California, United States with FDA, ISO, GMP, CE certificates.
The proposed mechanism of action of Solaraze gel in treating actinic keratoses is to block cyclo-oxygenase-2 (COX-2) to reduce angiogenesis and cellular proliferation. Topical diclofenac and hyaluronic acid, of which HA-E2.0 powder is a product, have been shown to be effective for topical treatments of actinic keratosis on the mucosal lip, with a minimum of irritation.
There’re now many generics of Solaraze on the market. Patients can check manufacturer’s PIL for information regarding the patent.
Due to the low systemic absorption of Solaraze, overdosage is highly unlikely as a result of topical use. However, the skin should be rinsed with water. No clinical cases of ingestion of Solaraze inducing overdosage have been reported.
If accidental ingestion resulting in significant systemic side effects occurs, general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatories should be used.
Side effects caused by using topical diclofenac include erythema, itching, dry skin, exfoliation, paresthesia, localized edema, application site reactions, and less frequently, photosensitivity.